Surviving cancer is often seen as a slim chance, you never know who may be affected by this disease and whether they would live to see the end of their treatment. However, bleak the odds may be, Linda ...

Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer and the fourth leading cause of cancer-related death, has a 5-year survival rate of less than 10%.1 The impact of pancreatic ...